dc.contributor.author | Popat, S | |
dc.contributor.author | Liu, SV | |
dc.contributor.author | Scheuer, N | |
dc.contributor.author | Hsu, GG | |
dc.contributor.author | Lockhart, A | |
dc.contributor.author | Ramagopalan, SV | |
dc.contributor.author | Griesinger, F | |
dc.contributor.author | Subbiah, V | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2022-09-06T13:07:34Z | |
dc.date.available | 2022-09-06T13:07:34Z | |
dc.date.issued | 2022-06-17 | |
dc.identifier | ARTN 3500 | |
dc.identifier | 10.1038/s41467-022-30908-1 | |
dc.identifier.citation | Nature Communications, 2022, 13 (1), pp. 3500 - | en_US |
dc.identifier.issn | 2041-1723 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5428 | |
dc.identifier.eissn | 2041-1723 | |
dc.identifier.eissn | 2041-1723 | |
dc.identifier.doi | 10.1038/s41467-022-30908-1 | |
dc.description.abstract | As advanced non-small cell lung cancer (aNSCLC) is being increasingly divided into rare oncogene-driven subsets, conducting randomised trials becomes challenging. Using real-world data (RWD) to construct control arms for single-arm trials provides an option for comparative data. However, non-randomised treatment comparisons have the potential to be biased and cause concern for decision-makers. Using the example of pralsetinib from a RET fusion-positive aNSCLC single-arm trial (NCT03037385), we demonstrate a relative survival benefit when compared to pembrolizumab monotherapy and pembrolizumab with chemotherapy RWD cohorts. Quantitative bias analyses show that results for the RWD-trial comparisons are robust to data missingness, potential poorer outcomes in RWD and residual confounding. Overall, the study provides evidence in favour of pralsetinib as a first-line treatment for RET fusion-positive aNSCLC. The quantification of potential bias performed in this study can be used as a template for future studies of this nature. | |
dc.format | Electronic | |
dc.format.extent | 3500 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | NATURE PORTFOLIO | en_US |
dc.relation.ispartof | Nature Communications | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Carcinoma, Non-Small-Cell Lung | |
dc.subject | Humans | |
dc.subject | Lung Neoplasms | |
dc.subject | Pyrazoles | |
dc.subject | Pyridines | |
dc.subject | Pyrimidines | |
dc.title | Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-05-25 | |
dc.date.updated | 2022-09-06T13:03:49Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1038/s41467-022-30908-1 | en_US |
rioxxterms.licenseref.startdate | 2022-06-17 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35715405 | |
pubs.issue | 1 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1038/s41467-022-30908-1 | |
pubs.volume | 13 | |
dc.contributor.icrauthor | Popat, Sanjay | |
icr.provenance | Deposited by Mr Arek Surman on 2022-09-06. Deposit type is initial. No. of files: 1. Files: Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in .pdf | |